Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, announced that it is part of a diverse research team of
international experts selected as awardees in this year’s Cancer
Grand Challenges competition. The team includes scientists,
physicians and patient advocacy groups from 10 institutions in the
United States, the United Kingdom, France, Germany and Austria and
will be led by Yael Mossé, M.D., Professor of Pediatrics and
Patricia Brophy Endowed Chair in Neuroblastoma Research at the
Children’s Hospital of Philadelphia, and Martin Eilers, Ph.D.,
Professor of Biochemistry and Molecular Biology at the University
of Würzburg, Germany.
The project entitled “Knocking Out Oncogenic Drivers and Curing
Childhood Cancers” (KOODAC) has the goal of developing orally
bioavailable targeted protein degraders that have the potential to
dramatically improve cure rates for children affected by solid
tumors. In this first-of-its-kind industry/academic discovery
partnership through Cancer Grand Challenges, Nurix will be making
in-kind contributions to address each of the five onco-fusion
targets, leveraging its DELigase technology to identify chemical
starting points for drug design and providing key expertise in TPD
optimization and development.
"Team KOODAC brings together an interdisciplinary, international
team of scientific experts, all sharing the vision of developing
safe and effective drugs against previously undruggable childhood
cancers," said Dr. Mossé. “We are excited to be working with Nurix,
an industry leader in targeted protein degradation.”
“We are proud to be invited to contribute our expertise in
protein degradation to this impressive team consisting of some of
the world's leading experts in pediatric cancers, oncoprotein
biology, and protein degradation,” said Gwenn M. Hansen, Ph.D.,
chief scientific officer at Nurix. “Being chosen to be a part of
this consortium and receiving this Cancer Grand Challenges
recognition is a testament to the power, potential and leadership
of Nurix’s targeted protein degradation technology to effectively
target oncogenic fusion proteins that, until now, have been
considered undruggable.”
Team KOODAC will focus on the development of TPDs and Molecular
Glue Degraders (MGDs) to target five key and previously undruggable
fusion proteins that have been shown to be drivers of high-risk
solid tumors in pediatric patients, including, MYCN, EWSR1-FLI,
DNAJB1-PRKACA, ALK, and PAX3/7-FOXO1, and conduct the preclinical
studies needed for biomarker-driven clinical trials.
The Cancer Grand Challenges is an initiative driven and funded
by Cancer Research UK, whose goal is to facilitate identification
of the greatest challenges in cancer today and to fund global teams
to work in innovative ways to find solutions. This year, five teams
were selected to receive funding of up to £20 million
(approximately $25 million) over a period of five years. The funds,
which will support only the academic groups involved in the
project, will be managed by Team KOODAC.
About Nurix Therapeutics, Inc.Nurix
Therapeutics is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of innovative
small molecules and antibody therapies based on the modulation of
cellular protein levels as a novel treatment approach for cancer,
inflammatory conditions, and other challenging diseases. Leveraging
extensive expertise in E3 ligases together with proprietary
DNA-encoded libraries, Nurix has built DELigase, an integrated
discovery platform, to identify and advance novel drug candidates
targeting E3 ligases, a broad class of enzymes that can modulate
proteins within the cell. Nurix’s drug discovery approach is to
either harness or inhibit the natural function of E3 ligases within
the ubiquitin-proteasome system to selectively decrease or increase
cellular protein levels. Nurix’s wholly owned, clinical stage
pipeline includes targeted protein degraders of Bruton’s tyrosine
kinase, a B-cell signaling protein, and inhibitors of Casitas
B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates
activation of multiple immune cell types including T cell and NK
cells. Nurix is headquartered in San Francisco, California. For
additional information visit http://www.nurixtx.com.
Forward-Looking StatementsThis press release
contains statements that relate to future events and expectations
and as such constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
When or if used in this press release, the words “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“outlook,” “plan,” “predict,” “should,” “will,” and similar
expressions and their variants, as they relate to Nurix, may
identify forward-looking statements. All statements that reflect
Nurix’s expectations, assumptions or projections about the future,
other than statements of historical fact, are forward-looking
statements, including, without limitation, statements regarding:
Nurix’s plans with respect to the KOODAC project the potential of
Nurix’s targeted protein degradation technology to target oncogenic
fusion proteins; the extent to which targeted protein degraders may
address a range of diseases; and the potential advantages of
Nurix’s scientific approach and DELigase™ platform. Forward-looking
statements reflect Nurix’s current beliefs, expectations, and
assumptions. Although Nurix believes the expectations and
assumptions reflected in such forward-looking statements are
reasonable, Nurix can give no assurance that they will prove to be
correct. Forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties and changes in
circumstances that are difficult to predict, which could cause
Nurix’s actual activities and results to differ materially from
those expressed in any forward-looking statement. Such risks and
uncertainties include, but are not limited to: (i) the risks
inherent in the drug development process, including the unexpected
emergence of adverse events or other undesirable side effects
during clinical development; (ii) uncertainties related to the
timing and results of clinical trials; (iv) whether Nurix will be
able to fund its research and development activities and achieve
its research and development goals; (v) the impact of economic and
market conditions and global and regional events on Nurix’s
business, clinical trials, financial condition, liquidity and
results of operations; (vi) whether Nurix will be able to protect
intellectual property and (vii) other risks and uncertainties
described under the heading “Risk Factors” in Nurix’s Annual Report
on Form 10-K for the fiscal year ended November 30, 2023, and other
SEC filings. Accordingly, readers are cautioned not to place undue
reliance on these forward-looking statements. The statements in
this press release speak only as of the date of this press release,
even if subsequently made available by Nurix on its website or
otherwise. Nurix disclaims any intention or obligation to update
publicly any forward-looking statements, whether in response to new
information, future events, or otherwise, except as required by
applicable law.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Apr 2023 to Apr 2024